Belinostat (Beleodaq) with CHOP for treatment of patients with peripheral T‐cell lymphoma, 1st line

Peripheral T-cell lymphoma (PTCL) is a rare form of lymphoma, a cancer affecting a type of white blood cell called a lymphocyte. At the beginning, the symptoms of lymphoma can be very varied and difficult to diagnose, but as the lymph nodes get bigger, a painless swelling in the neck, armpit or groin is sometimes noticed. The condition generally affects people aged over 60 years of age and it is slightly, more common in men than in women. By the time they are diagnosed, the lymphoma has often spread widely around the body. The main treatment is chemotherapy, but not all patients are well enough to manage this and the disease often returns after treatment.
Belinostat is a new drug under development for the treatment of peripheral T-cell lymphoma. The safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line chemotherapies for the treatment of PTCL. Belinostat is given as a single injection in a dosing regimen that involves a 21-day cycle.